Vasily M. Gelfanov

机构：Novo Nordisk (United States) · ORCID：0000-0001-5216-5227

发表论文 71 篇 · 总被引 4953 次 · h-index 25

代表论文

• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans (2013 · Science Translational Medicine · 被引 693)
• A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents (2014 · Nature Medicine · 被引 644)
• Targeted estrogen delivery reverses the metabolic syndrome (2012 · Nature Medicine · 被引 340)
• Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions (2013 · Diabetes · 被引 245)
• Unimolecular Polypharmacy for Treatment of Diabetes and Obesity (2016 · Cell Metabolism · 被引 237)
• Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism (2018 · Molecular Metabolism · 被引 232)